Lybalvi

Schizophrenia

Lybalvi is used for the treatment of schizophrenia in adults. It helps manage the symptoms of the condition, which may include hallucinations, delusions, and social withdrawal.

Bipolar I Disorder

This medication is also used to treat adults with bipolar I disorder. It is prescribed for several specific purposes within this condition:

• Acute Treatment: It is used to treat sudden manic or mixed episodes.
• Maintenance Treatment: It is used as a long-term therapy to help prevent the return of manic or mixed symptoms.
• Combination Therapy: Lybalvi can be used alone or as an add-on treatment with other medications, such as lithium or valproate, to manage bipolar symptoms.

Mechanism of Action

Lybalvi contains two different active ingredients that work together to treat schizophrenia and bipolar I disorder. The exact way the medication works is not fully understood, but it involves the following processes:

• Olanzapine: This component is an atypical antipsychotic. It is believed to work by affecting the activity of neurotransmitters, which are chemical messengers in the brain. Specifically, it targets dopamine and serotonin receptors. By balancing these chemicals, it helps to improve thinking, mood, and behavior.
• Samidorphan: This component is an opioid antagonist. It does not treat the symptoms of mental health disorders directly. Instead, it is included to help reduce the weight gain that is commonly associated with taking olanzapine. It works by blocking specific opioid receptors in the body, which may help manage metabolic side effects.

By combining these two ingredients, the medication aims to provide the antipsychotic benefits of olanzapine while mitigating some of the metabolic challenges often seen with this type of treatment.

Common Side Effects

The most frequently reported side effects of Lybalvi include:

• Weight gain
• Sleepiness or extreme tiredness
• Dry mouth
• Headache
• Increased appetite
• Dizziness
• Constipation
• Back pain
• Speech problems

Serious Side Effects

Some side effects can be severe and require immediate medical attention. These may include:

• Metabolic changes: High blood sugar (hyperglycemia), increased cholesterol and triglyceride levels, and significant weight gain.
• Movement disorders: Uncontrolled body movements, particularly in the face or tongue (tardive dyskinesia), or a rare, life-threatening reaction called neuroleptic malignant syndrome (NMS).
• Opioid withdrawal: Because Lybalvi contains samidorphan, it can cause sudden and severe withdrawal symptoms in people who are currently using or have recently used opioid medications.
• Low blood pressure: Feeling dizzy or faint when standing up too quickly (orthostatic hypotension).
• Low white blood cell count: This can make it harder for the body to fight infections.
• Seizures: An increased risk of convulsions in some patients.
• Difficulty swallowing: Problems with the muscles used for swallowing, which may lead to food entering the lungs.
• Temperature regulation: Difficulty cooling down after exercise or in hot environments.

Boxed Warning: Dementia-Related Psychosis

Elderly patients with dementia-related psychosis who are treated with antipsychotic drugs are at an increased risk of death. Lybalvi is not approved for the treatment of patients with dementia-related psychosis.

Opioid-Related Risks

Lybalvi contains samidorphan, a medication that blocks the effects of opioids. This creates specific safety risks:

• Severe Opioid Withdrawal: If Lybalvi is taken while opioids are in the system or during acute withdrawal, it can cause sudden and severe withdrawal symptoms that may require hospitalization.
• Risk of Opioid Overdose: Attempting to overcome the effects of Lybalvi by taking large doses of opioids can lead to a life-threatening or fatal overdose.
• Contraindication: This medication must not be used by individuals currently using opioids or those undergoing acute opioid withdrawal.

Serious Reactions and Conditions

Neuroleptic Malignant Syndrome (NMS)

NMS is a rare but potentially fatal reaction to antipsychotic medications. Symptoms may include high fever, muscle stiffness, confusion, and changes in heart rate or blood pressure.

Tardive Dyskinesia

This condition involves uncontrollable body movements, often affecting the face, tongue, or jaw. The risk of developing tardive dyskinesia increases with the duration of treatment and the total cumulative dose, and it may become permanent.

Metabolic Changes

Lybalvi can cause significant metabolic changes, including:

• Hyperglycemia and Diabetes: High blood sugar levels can occur, which in extreme cases may lead to ketoacidosis, coma, or death.
• Dyslipidemia: Changes in cholesterol and triglyceride levels may occur.
• Weight Gain: Significant weight gain is a known risk and should be monitored by a healthcare provider.

Other Precautions

Lybalvi may cause orthostatic hypotension, which is a sudden drop in blood pressure when standing up that can lead to dizziness, fainting, or falls. It may also increase the risk of seizures, lower white blood cell counts, and impair the body's ability to regulate its core temperature. Patients should be monitored for these conditions throughout treatment.

Pregnancy

There is limited data regarding the use of Lybalvi in pregnant individuals. However, using antipsychotic medications like olanzapine during the third trimester of pregnancy may cause problems in the newborn after delivery. These potential issues include:

• Withdrawal symptoms
• Agitation or tremors
• Muscle stiffness or floppiness
• Drowsiness
• Breathing or feeding difficulties

The severity of these symptoms can vary; some newborns recover within hours or days, while others may require hospitalization. If you become pregnant while taking Lybalvi, do not stop the medication without consulting your doctor, as untreated mental health conditions can also pose risks. There is a pregnancy exposure registry available to monitor the health of individuals and their infants who are exposed to antipsychotics during pregnancy.

Breastfeeding

Olanzapine, one of the components of Lybalvi, is known to pass into human breast milk. It is currently unknown if samidorphan passes into human breast milk, though it has been detected in animal studies. Because of the potential for side effects in a nursing infant, such as excessive sleepiness, healthcare providers typically weigh the benefits of breastfeeding against the mother's clinical need for the medication and any potential adverse effects on the child.

Available Forms

Lybalvi is supplied as film-coated tablets for oral administration. This medication is a fixed-dose combination, meaning each tablet contains both olanzapine and samidorphan.

FDA Approval and Indications

The U.S. Food and Drug Administration (FDA) approved Lybalvi in June 2021. It is a combination of olanzapine, an atypical antipsychotic, and samidorphan, an opioid antagonist. The medication is indicated for the treatment of adults with:

• Schizophrenia
• Bipolar I disorder, including acute treatment of manic or mixed episodes as a single therapy or as an add-on to lithium or valproate, and for maintenance treatment.

Boxed Warning

Lybalvi contains a boxed warning, the FDA's most serious type of warning, regarding its use in elderly patients with dementia-related psychosis. Clinical studies have shown that elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Lybalvi is not approved for the treatment of patients with dementia-related psychosis.

Regulatory History

The approval was based on data from clinical trials that evaluated the safety and efficacy of the combination, specifically focusing on weight gain associated with olanzapine. While it is a prescription medication, it is not classified as a controlled substance.

Weight Management and Lybalvi

Weight gain is a common side effect of many antipsychotic medications, particularly olanzapine. Lybalvi combines olanzapine with samidorphan, a drug intended to help reduce the amount of weight gained during treatment.

Clinical Findings

In clinical studies, patients taking Lybalvi generally experienced less weight gain compared to those taking olanzapine alone. However, weight gain is still a common side effect of the medication, and individual results vary.

Monitoring and Management

• Regular Check-ups: Healthcare providers typically monitor weight and waist circumference regularly while a patient is taking this medication.
• Metabolic Changes: Because weight gain can be linked to changes in blood sugar and cholesterol levels, routine blood tests may be required to monitor for metabolic side effects.
• Lifestyle Adjustments: Maintaining a balanced diet and regular physical activity is often recommended to help manage weight while on this therapy.

If you notice significant or rapid weight gain, it is important to discuss these changes with a healthcare professional to determine the best course of action.